A Survey on Thyroid Hormonal Status among Moderate to Severe Stable Chronic Obstructive Pulmonary Disease
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 3 No. 4(Autumn) (2013),
2 December 2013
,
Page 106-113
https://doi.org/10.22037/ijmtfm.v3i4(Autumn).3643
Abstract
Background:COPD is one of the common diseases in pulmonary medicine. Current knowledge indicated that there was a link between COPD with thyroid hormonal abnormalities. Thyroid function disturbances can be able to affect on the COPD through upper airway obstruction,respiratory muscle weakness, development of central and obstructive sleep apnea,alveolar hypoventilation, and pleural effusion. Thyroid abnormalities are often both detectable and treatable. The aim of the study is to assessserum levels of thyroid hormones among moderate to severe stable COPD patients.
Methods: 34 men were enrolled consecutive among established and stable COPD patients with moderate to the severe stages. Their selection constructed on the ATS/GOLD guidelines. Thyroid functions and hormonal concentrations measured according to manufacturer's instructions.
Results:Mean age of sample was 51.7±5.76SD years. It ranged over 42–60 years (Mode=49). Significant thyroid hormonal abnormalities were detected among established moderate to the severe COPD patients. The mean±SD of TSH, TT4 and free T3 concentrations in the focus population was 2.36±1.53 microIU/ml, 12.15±2.15 Micro/dl and 2.20±0.45 pg/ml, respectively. Frequency distribution of thyroid disorders included euthyroid functions 76.5%; three subjects of those had euthyroid sick syndrome, subclinical hyperthyroidism 20.6% and over hypothyroidism 2.9%, respectively. Grades of goiter on WHO classifications observed 0=44% and 1=41%.
Conclusion:Frequent exacerbations of thyroid disorders were detected among stable, moderate to severe COPD patients. Subclinical hyperthyroidism and euthyroid sick syndrome were significant. Despite that prevalence of hypothyroidism is considerable in age-rang of Iranian’s population.
- Chronic Obstructive
- Pulmonary Disease
- Thyroid Hormones
- Hyperthyroidism
- Goiter
- Pulmonary Function Test
How to Cite
References
References
Dimopoulou I, Ilias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism. 2001;50(12):1397-401.
Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care. 2003;48(12):1185-1191.
Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269-80.
Barrère X, Valeix P, Preziosi P, Bensimon M, Pelletier B, Galan P, Hercberg S. Determinants of thyroid volume in healthy French adults participating in the SU.VI MAxx cohort. ClinEndocrinol (Oxf). 2000;52(3):273-278.
Hansen PS, Brix TH, Bennedbaek FN, Bonnema SJ, Kyvik KO, Hegedüs L. Genetic and environmental causes of individual differences in thyroid size: a study of healthy Danish twins. J ClinEndocrinolMetab. 2004;89(5):2071-2077.
Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Cigarette smoking and risk of clinically overt thyroid disease: a population–based twin case control study. Arch Intern Med. 2000;160(5):661-6.
Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders.Eur J Endocrinol. 2005;152(4):491-499.
Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. EurRespir J. 2003;21(2):347-60.
Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574-80.
Brüssel T, Matthay MA, Chernow B. Pulmonary manifestations of endocrine and metabolic disorders. Clin Chest Med. 1989;10(4):645-53.
Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46(8):798-825.
Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. EurRespir J. 2004;23(6):932-46
COPD ATS-ERS 2.0 - American Thoracic Society. available at: www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf
Galanti MR, Granath F, Cnattingius S, Ekbom-Schnell A, Ekbom A. Cigarette smoking and the risk of goitre and thyroid nodules amongst parous women. J Endocrinol Invest. 2005;28(5):469-78.
NHLBI/WHO global initiative for chronic obstructive lung disease(GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease(update 2005).
World Health Organization, United Nations Children’s Fund, and International Council for Control of Iodine Deficiency Disorders. Indicators for assessing iodine deficiency disorders and their control through salt iodization. Geneva: World Health Organization, 1994. (WHO/NUT 94.6).
WHO Expert Committee. Physical status: The use and interpretation of anthropometry. WHO technical report series no:854. 1995, Geneva, WHO.
Karadag F, Karul AB, Cildag O, Altun C, Gurgey O. Determinants of BMI in patients with COPD. Respirology 2004;9:70–75.
Jamson LJ, weetman AD. Disease of thyroid gland. In:Fauci AS, Dennis L. Kasper, Dan L. Longo, Eugene Braunwald, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo. Harrison's Principles of Internal Medicine17th edition. New York: MacGrow- Hill; 2005;2104-2126.
Karakaya A, Tunçel N, Alptuna G, Koçer Z, Erbay G. Influence of cigarette smoking on thyroid hormone levels. Hum Toxicol. 1987;6(6):507-509.
Utiger RD. Effects of smoking on thyroid function..Eur J Endocrinol. 1998;138(4):368-369.
Fukayama H, Nasu M, Murakami S, Sugawara M.. Examination of antithyroid effects of smoking products in cultured thyroid follicles: only thiocyanate is a potent antithyroid agent. ActaEndocrinol (Copenh). 1992;127(6):520-525.
Fisher CL, Mannino DM, Herman WH, Frumkin H. Cigarette smoking and thyroid hormone levels in males. Int J Epidemiol. 1997;26(5):972-977.
Sugawara M, Park DL, Hershman JM. Antithyroid effect of 2,3-dihydroxypyridine in vivo and in vitro. ProcSocExpBiol Med. 1982;170(4):431-435.
Azizi F, Mehran L. Experiences in the prevention, control, and elimination of iodine deficiency disorders: a regional perspective. East Mediterr Health J. 2004;6:761 – 770.
Azizi F, Navai L, Fattahi F. Goiter prevalence, urinary iodine excretion, thyroid function, and anti-thyroid antibodies after 12 years of salt iodization in Shahriar, Iran. Int J VitamNutr Res. 2002; 72:291–295.
Semple PD, Beastall GH, Watson WS, Hume R. Hypothalamic-pituitary dysfunction in respiratory hypoxia. Thorax. 1981;36(8):605-609.
Bratel T, Wennlund A, Carlström K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med. 2000;94(12):1221-8.
Okutan O, Kartaloglu Z, Onde ME, Bozkanat E, Kunter E. Pulmonary function tests and thyroid hormone concentrations in patients with chronic obstructive pulmonary disease. Med PrincPract. 2004;13(3):126-128.
Bratel T, Wennlund A, CarlströmK.. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med. 2000;94(12):1221-1228.
Semple PD, Semple CG, Beastall GH, Brown TM, Watson WS, Hume R. Endocrine studies in cyanotic congenital heart disease. Scott Med J. 1985;30(1):25-29.
Boelen A, Platvoet-TerSchiphorst MC, Wiersinga WM. Associated between serum interlukin-6 and serum 3,5,3,,-tiiodothyronin in non-thyroidal illness. J ClinEndocrinolMetab. 1993;77(6):1695-9.
Dimopoulou I, I˙lias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity chronic obstructive pulmonary disease on thyroid function. Metabolism 2001;50(12):1397–401.
Mechanick JI, Brett EM. Endocrine and metabolic issues in the management of the chronically, critically ill patient. Crit Care Clin. 2002;18(3):619-41.
Chopra IJ. Euthyroid sick syndrome: is it a misnomer? J ClinEndocrinolMetab 1996;82(2):329–34.
Davies PH, Black EG, Sheppard MC, Franklyn JA. Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness. ClinEndocrinol 1996;44:199–205.
Hamilton MA. Prevalence and clinical implications of abnormal thyroid hormone metabolism in advanced heart failure. Ann ThoracSurg 1993;56(Suppl 1):48–52.
Slag MF, Morley JE, Elson MK, Crowson TW, Nettle FQ, Shafer RB. Hypothyroxinemia in critically ill patients as a predictor of high mortality. J Am Med Assoc 1981;245:43–45.
Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, etal.The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham survey. ClinEndocrinol (Oxf). 1995;43(1):55-68.
Chiovato L, Mariotti S, Pinchera A. Thyroid diseases in the elderly. BaillieresClinEndocrinolMetab. 1997;11(2):251-70.
Martinez FJ, Bermudez-Gomez M, Celli BR. Hypothyroidism. A reversible cause of diaphragmatic dysfunction. Chest 1989; 96: 159-63.
Anthony D.Toft Subclinical hyperthyroidism The New England Journal of Medicine. Boston: 2001;7(4):512-515.
Fatourechi V. Adverse effects of subclinical hyperthyroidism. The Lancet.2001;4(2):358-363.
- Abstract Viewed: 432 times
- PDF Downloaded: 313 times